[Treatment of hypercholesterinemia with beta-pyridylcarbinol. II. Side effects and disscussion].
D000328:Adult; D000787:Angina Pectoris / Q000188:drug therapy; D001161:Arteriosclerosis / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000188:drug therapy; D003692:Delayed-Action Preparations; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D005951:Glucose Tolerance Test; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006940:Hyperemia / Q000139:chemically induced*; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D014665:Vasodilator Agents / Q000009:adverse effects*; D014973:Xanthomatosis / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D009539:Nicotinic Acids; D011725:Pyridines; D014665:Vasodilator Agents
Behandlung der Hypercholesterinämie mit Beta-Pyridylkarbinol. II. Nebenwirkungen und Diskussion.